D
Daniel H. Present
Researcher at Mount Sinai Hospital
Publications - 153
Citations - 22153
Daniel H. Present is an academic researcher from Mount Sinai Hospital. The author has contributed to research in topics: Ulcerative colitis & Infliximab. The author has an hindex of 51, co-authored 153 publications receiving 21110 citations. Previous affiliations of Daniel H. Present include Beth Israel Medical Center & Lenox Hill Hospital.
Papers
More filters
Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
TL;DR: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Journal ArticleDOI
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
Stephan R. Targan,Stephen B. Hanauer,S. J. H. Van Deventer,Lloyd Mayer,Daniel H. Present,T. Braakman,K. L. Dewoody,T. F. Schaible,Paul Rutgeerts +8 more
TL;DR: A 12-week multicenter, double-blind, placebo-controlled trial of cA2 in 108 patients with moderate-to-severe Crohn's disease that was resistant to treatment, finding clinical response, the primary end point, was a reduction of 70 or more points in the score on theCrohn's Disease Activity Index at four weeks.
Journal ArticleDOI
Infliximab for the treatment of fistulas in patients with Crohn's disease.
Daniel H. Present,Paul Rutgeerts,Stephan R. Targan,Stephen B. Hanauer,Lloyd Mayer,R. A. van Hogezand,Daniel K. Podolsky,Bruce E. Sands,T. Braakman,K. L. Dewoody,Th.F. Schaible,S. J. H. Van Deventer +11 more
TL;DR: Infliximab is an efficacious treatment for fistulas in patients with Crohn's disease and the most common adverse events for patients treated with infliximab were headache, abscess, upper respiratory tract infection, and fatigue.
Journal ArticleDOI
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy
Simon Lichtiger,Daniel H. Present,Asher Kornbluth,Irwin M. Gelernt,Joel J. Bauer,Greg Galler,Fabrizio Michelassi,Stephen B. Hanauer +7 more
TL;DR: Intravenous cyclosporine therapy is rapidly effective for patients with severe corticosteroid-resistant ulcerative colitis.
Journal ArticleDOI
Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study.
Daniel H. Present,Burton I. Korelitz,Nathaniel Wisch,Joseph L. Glass,David B. Sachar,Bernard S. Pasternack +5 more
TL;DR: 6-MP is an effective and useful agent in the management of Crohn's disease and was more effective than placebo in closing fistulas and in permitting discontinuation or reduction of steroid dosage.